Actinogen Medical Limited (AU:ACW)
ASX:ACW
Want to see AU:ACW full AI Analyst Report?
ACW Stock Chart & Stats
AU$0.04
>-AU$0.01(-3.85%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-3.85%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.07
Previous CloseN/A
Volume244.11K
Average Volume (3M)6.03M
Market Cap
AU$158.03M
Enterprise ValueAU$151.86M
Total Cash (Recent Filing)AU$6.53M
Total Debt (Recent Filing)AU$366.31K
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,591,539,800
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.74
Price to Sales (P/S)12.48
P/FCF Ratio-9.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.50M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA low debt-to-equity ratio and healthy equity base give the company financial flexibility to sustain long R&D timelines without significant interest burden. This reduces bankruptcy risk, preserves optionality for partnering or milestone financing, and supports steady funding of clinical programs.
High Gross Profit MarginA reported 100% gross margin indicates the company's core science and development activities currently incur minimal COGS, implying attractive unit economics if commercialized. Structurally, high gross margin potential supports scalable profitability once revenue ramps and fixed R&D overheads are leveraged.
Focused R&D Pipeline (xanamem / 11β-HSD1)A clear, focused scientific strategy targeting 11β-HSD1 with xanamem concentrates resources on a defined mechanism and patient populations (neuropsychiatric/neurodegenerative). This focus can accelerate proof-of-concept, attract partnerships, and create differentiated IP and clinical positioning versus unfocused biotech peers.
Bears Say
Declining Revenue And Persistent LossesA steep revenue decline and ongoing negative net, EBIT and EBITDA margins indicate the company is not generating commercial cash inflows. Persisting losses erode equity, increase reliance on external funding, and constrain the firm’s ability to self-fund later-stage trials or commercialization without dilution or strategic partnerships.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow reduces runway and raises material funding risk. Over time this forces capital raises or partner dependence, which can dilute shareholders and slow program timelines. Weak cash generation also limits the firm's ability to scale trials or react to regulatory demands.
Very Small Workforce And Operational CapacityAn employee base of six implies heavy reliance on external CROs, consultants and partners for trial execution, regulatory work and scale-up. This creates execution risk, potential delays, key-person dependency and limits internal capability to run simultaneous programs or a late-stage commercialization build-out efficiently.
Actinogen Medical News
ACW FAQ
What was Actinogen Medical Limited’s price range in the past 12 months?
Actinogen Medical Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Actinogen Medical Limited’s market cap?
Actinogen Medical Limited’s market cap is AU$158.03M.
When is Actinogen Medical Limited’s upcoming earnings report date?
Actinogen Medical Limited’s upcoming earnings report date is Sep 02, 2026 which is in 130 days.
How were Actinogen Medical Limited’s earnings last quarter?
Actinogen Medical Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Actinogen Medical Limited overvalued?
According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued.
Does Actinogen Medical Limited pay dividends?
Actinogen Medical Limited does not currently pay dividends.
What is Actinogen Medical Limited’s EPS estimate?
Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinogen Medical Limited have?
Actinogen Medical Limited has 3,591,539,800 shares outstanding.
What happened to Actinogen Medical Limited’s price movement after its last earnings report?
Actinogen Medical Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Actinogen Medical Limited?
Currently, no hedge funds are holding shares in AU:ACW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinogen Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.08 (100.00% Upside)
AU$0.08 (100.00% Upside)
Blogger Sentiment
Bullish
AU:ACW Sentiment 88%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$667.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-134.14%
Trailing 12-Months
Asset Growth
-55.10%
Trailing 12-Months
Company Description
Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
ACW Stock 12 Month Forecast
Average Price Target
AU$0.08
▲(100.00% Upside)
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---